Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × NSCLC × Tyrosine Kinase Inhibitors × Clear all

Phase

Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm, Residual 1 NSCLC 1 Carcinoma, Hepatocellular 1

Interventions

Pemetrexed 2 Gefitinib 2 spartalizumab 1 aflutinib 1 Tyrosine Kinase Inhibitors 1 Thalidomide 1 Radiosurgery 1 Platinum 1 Immune Checkpoint Inhibitors 1 Drug Therapy 1 Axitinib 1 Aspirin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03256981 2023-12-26

HALT

Institute of Cancer Research, United Kingdom

Phase 2/3 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡